A First-in-Patient Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A First-in-Patient Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease	Digestive System Diseases, Nutritional and Metabolic Diseases, celiac disease, digestive system disorder, intestinal disorder, malabsorption syndrome, metabolic disease	Recruiting	Phase 1	2026-07-28		NCT07377565

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	617
Nielsen Fernandez-Becker	1
Stanford's Innovative Medicines Accelerator	1

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Stanford University	Stanford	United States	213